Global Obesity Treating Neuromodulation System Market Size By Type (Vagus Nerve Stimulator, Splanchnic Nerve Stimulator), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to...

The Global Obesity Treating Neuromodulation System Market was valued at USD 418 million in 2023 and is anticipated to surpass USD 1.12 billion by 2031, growing at a CAGR of 12.9% during the forecast period of 2023–2031. The rising prevalence of obesity worldwide, growing awareness of non-invasive treatment alternatives, and increasing technological advancements in neuromodulation are key contributors to the market’s expansion. Neuromodulation systems provide promising outcomes in managing obesity by targeting hunger-regulating brain regions or nerves, particularly the vagus nerve, offering safer alternatives to surgical interventions.

Drivers:

Rising Global Obesity Rates:

A major driver of this market is the sharp increase in obesity prevalence. According to WHO, over 1 billion people globally are obese. This escalating burden has prompted increased demand for alternative and sustainable treatment options like neuromodulation.

Technological Advancements in Neuromodulation Devices:

Continuous innovation in device miniaturization, battery life, and targeted nerve stimulation is enhancing the efficacy and acceptance of obesity treatment neuromodulation systems. The integration of AI in neuromodulation protocols is also emerging as a critical development.

Patient Preference for Non-Surgical Treatment:

As bariatric surgery carries notable risks and post-operative complications, many patients prefer neuromodulation therapies, which are less invasive, reversible, and come with lower side effects.

Restraints:

High Device Cost and Limited Insurance Coverage:

Despite their clinical promise, the adoption of neuromodulation systems is often hindered by high upfront costs and inconsistent insurance reimbursement, especially in developing countries.

Lack of Long-term Efficacy Data:

While short-term results are promising, a limited number of longitudinal studies confirming the long-term success of obesity treating neuromodulation systems may deter healthcare providers and patients from adopting this treatment modality widely.

Opportunity:

Expansion into Emerging Markets:

Rapid urbanization and changing dietary patterns in emerging economies are increasing obesity rates, providing a fertile ground for the adoption of neuromodulation therapies, particularly as healthcare infrastructure improves.

Integration with Digital Health Monitoring Systems:

There is growing potential to combine neuromodulation devices with smart health apps and wearable technologies, enabling real-time monitoring, personalized adjustments, and enhanced treatment outcomes.

Market by System Type Insights:

The Vagal Nerve Stimulation (VNS) segment held the largest market share in 2023 and is projected to maintain dominance throughout the forecast period. VNS systems effectively modulate hunger signals sent to the brain, helping patients manage appetite and food intake. Non-invasive and implantable VNS devices are both gaining traction for their success rates and lower side-effect profiles.

Other segments, such as Deep Brain Stimulation (DBS) and Spinal Cord Stimulation (SCS), are also being researched and developed, particularly for severe and treatment-resistant cases of obesity.

Market by End-use Insights:

In terms of end-use, Specialty Clinics dominated the market in 2023. These clinics offer personalized treatment approaches, dedicated obesity programs, and often serve as early adopters of innovative technologies such as neuromodulation.

Hospitals are also significant contributors, with their growing incorporation of neuromodulation in multidisciplinary obesity treatment protocols. Home-based treatment settings are expected to witness faster growth due to advances in remote monitoring and wearable neuromodulation devices.

Market by Regional Insights:

North America led the global obesity treating neuromodulation system market in 2023, backed by a high obesity burden, favorable reimbursement structures, and early adoption of advanced technologies.

Asia-Pacific is forecasted to grow at the fastest CAGR, driven by the rapidly increasing prevalence of obesity, urbanization, and rising healthcare investments in countries such as China, India, and South Korea.

Europe also holds a significant market share due to the presence of several medical device innovators and favorable regulatory pathways for neuromodulation technologies.

Competitive Scenario:

Key players operating in the global obesity treating neuromodulation system market include:

ReShape Lifesciences Inc.

EnteroMedics Inc. (now vBloc)

IntraPace Inc.

LivaNova PLC

Medtronic plc

BioControl Medical

NeuroMetrix Inc.

These companies are actively investing in R&D, conducting clinical trials, and seeking regulatory approvals to expand their product portfolios and global presence.

Scope of Work – Global Obesity Treating Neuromodulation System Market

Report Metric Details

Market Size (2023) USD 418 million

Projected Market Size (2031) USD 1.12 billion

CAGR (2023–2031) 12.9%

Market Segments By System Type (VNS, DBS, SCS), By End-use, Region

Growth Drivers Rising obesity rates, non-invasive preference, tech advancement

Opportunities Emerging markets, digital integration in treatment

Key Market Developments:

2023: ReShape Lifesciences launched an updated version of its vBloc neuromodulation device with remote monitoring capabilities.

2024: Medtronic initiated clinical trials for a novel transcutaneous vagal nerve stimulator designed for home use.

2025: LivaNova collaborated with leading research institutes to develop a personalized AI-driven DBS system for obesity.

FAQs:

What is the current market size of the Global Obesity Treating Neuromodulation System Market?

The market was valued at USD 418 million in 2023.

What is the major growth driver of the Global Obesity Treating Neuromodulation System Market?

The primary driver is the rising prevalence of obesity and the growing preference for non-invasive treatment options.

Which is the largest region during the forecast period in the Global Obesity Treating Neuromodulation System Market?

North America is the leading region due to high obesity rates and advanced healthcare infrastructure.

Which segment accounted for the largest market share in the Global Obesity Treating Neuromodulation System Market?

The Vagal Nerve Stimulation (VNS) segment held the largest share in 2023.

Who are the key market players in the Global Obesity Treating Neuromodulation System Market?

Key players include ReShape Lifesciences, Medtronic, LivaNova, EnteroMedics, and IntraPace.